CD274 and neoplasm: Similarly, in the clinical trial by Bear et al., 2025, decitabine combined with pembrolizumab increased both stromal and intratumoral tumor-infiltrating lymphocytes (TILs) and elevated PD-L1 expression, reflecting a transition toward a more inflamed tumor microenvironment [52].